Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry.

Biomed Res Int · 2014 · PMC3977430 · PMID 24779005

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In the HER2-negative group ( n = 2,727, 219 events) patients receiving only AHT (HR = 2.33, 95%-CI 1.40–3.87, P = 0.001) or only CHT (HR = 3.15, 95%-CI 1.61–6.16, P = 0.001) or no adjuvant therapy at all (HR = 4.91, 95% CI 2.81–8.59, P < 0.001) showed a highly significant decrease in OS compared to patients with both CHT and AHT (reference group) ( Table 6(b) ). 4.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.